Form 4: Roivant CFO Sells Shares for Tax Obligations

Roivant Sciences CFO Richard Pulik disposed of 2,129 common shares to cover tax withholding obligations related to RSU vesting, as per a pre-planned transaction.

Summary

• Richard Pulik, Chief Financial Officer (CFO) of Roivant Sciences Ltd. (ROIV), reported a transaction involving the company's common shares.
• The transaction, dated December 20, 2025, involved the disposition of 2,129 common shares.
• This disposition was a 'net settlement' by Roivant Sciences to satisfy applicable tax withholding obligations in connection with the vesting and settlement of previously granted Restricted Stock Units (RSUs).
• The shares were disposed of at a price of $22.41 per share.
• Following this transaction, Richard Pulik beneficially owns 386,144 common shares directly.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary insider transaction related to tax withholding on RSU vesting, which is neutral in terms of company performance or outlook.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, but it does indicate a pre-planned transaction for future RSU vesting and tax settlement.

Industry Context

This transaction is a routine insider filing common across all industries, particularly for executives receiving equity compensation like Restricted Stock Units (RSUs). The 'net settlement' to cover tax obligations upon vesting is a standard practice, often pre-arranged under a Rule 10b5-1 plan to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The disposition of shares to cover tax withholding upon RSU vesting is a standard and widely accepted practice for executive compensation in publicly traded companies, aligning with common industry benchmarks.
• The use of a Rule 10b5-1 plan for such transactions is also a common corporate governance practice, demonstrating adherence to regulatory best practices for insider trading compliance.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact beyond the reporting person, as it relates to individual executive compensation.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by Roivant Sciences' CFO to cover tax obligations upon RSU vesting, executed under a Rule 10b5-1 plan. Such a transaction is a standard part of executive compensation and does not reflect a change in the company's operational performance, strategic direction, or management's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based solely on this filing.

Keywords

Roivant Sciences, ROIV, Form 4, Insider Transaction, Richard Pulik, CFO, RSU, Tax Withholding, Equity Compensation, 10b5-1 Plan